Marktanalyse - Alopecia - Pipeline Review, H1 2017

Global Markets Direct
02.2017
156 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Alopecia - Pipeline Review, H1 2017


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Alopecia — Pipeline Review, H1 2017, provides an overview of the Alopecia (Dermatology) pipeline landscape.

Alopecia is the partial or complete loss of hair especially on the scalp either in patches, on the entire head or over the entire body. Thinning hair is the most obvious symptom. The predisposing factors include allergies, irritants, toxins, burns, injuries, and infections.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Alopecia — Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alopecia (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alopecia (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Alopecia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 1, 15, 4, 1, 18 and 8 respectively. Similarly, the Universities portfolio in Phase III and Discovery stages comprises 1 and 1 molecules, respectively.

Alopecia (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Alopecia (Dermatology).
- The pipeline guide reviews pipeline therapeutics for Alopecia (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Alopecia (Dermatology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Alopecia (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Alopecia (Dermatology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Alopecia (Dermatology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Alopecia (Dermatology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Alopecia - Overview 7

Alopecia - Therapeutics Development 8

Pipeline Overview 8

Pipeline by Companies 9

Pipeline by Universities/Institutes 12

Products under Development by Companies 13

Products under Development by Universities/Institutes 16

Alopecia - Therapeutics Assessment 17

Assessment by Target 17

Assessment by Mechanism of Action 20

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Alopecia - Companies Involved in Therapeutics Development 27

Aclaris Therapeutics Inc 27

Allergan Plc 27

Almirall SA 28

AndroScience Corp 28

Berg LLC 29

BiologicsMD Inc 29

BirchBioMed Inc 30

Bristol-Myers Squibb Company 30

Cassiopea SpA 31

Concert Pharmaceuticals Inc 31

Dong-A Socio Holdings Co Ltd 32

Follicum AB 32

Handok Inc 33

Histogen Inc 33

Hyundai Pharmaceutical Co Ltd 34

Incyte Corp 34

Kuhnil Pharmaceutical Co Ltd 35

Lee's Pharmaceutical Holdings Ltd 35

LEO Pharma A/S 36

Medivir AB 36

NovaLead Pharma Pvt Ltd 37

Novartis AG 37

Panacea Biotec Ltd 38

Pfizer Inc 38

Quark Pharmaceuticals Inc 39

RiverTown Therapeutics Inc 39

RXi Pharmaceuticals Corp 40

Samumed LLC 40

SWITCH Biotech LLC 41

Taisho Pharmaceutical Holdings Co Ltd 41

Tigo GmbH 42

viDA Therapeutics Inc 42

Alopecia - Drug Profiles 43

(cyclosporine A + minoxidil + RT-175) - Drug Profile 43

abatacept - Drug Profile 44

AI-001 - Drug Profile 51

Antibodies to Inhibit Heparanase for Alopecia, Colitis, Diabetic Nephropathy, Transplantation and Oncology - Drug Profile 52

Antisense Oligonucleotide to Inhibit Androgen Receptor for Alopecia - Drug Profile 53

ASCJ-9 - Drug Profile 54

ATI-50001 - Drug Profile 56

ATI-50002 - Drug Profile 57

ATI-50003 - Drug Profile 58

bimatoprost - Drug Profile 59

BMD-1141 - Drug Profile 61

BMD-1341 - Drug Profile 62

BMD-2341 - Drug Profile 63

BQ-A - Drug Profile 64

BRM-421 - Drug Profile 65

calcitriol - Drug Profile 66

CB-0301 - Drug Profile 67

CTP-543 - Drug Profile 70

DHL-HisZnNa - Drug Profile 72

finasteride - Drug Profile 73

finasteride - Drug Profile 74

FOL-005 - Drug Profile 75

HGEN-001 - Drug Profile 78

HL-5945 - Drug Profile 80

HTB-005 - Drug Profile 81

interferon beta-1b - Drug Profile 82

KI-1104 - Drug Profile 83

KI-1105 - Drug Profile 84

LEO-124249 - Drug Profile 85

minoxidil - Drug Profile 86

NLP-602 - Drug Profile 87

OLX-104 - Drug Profile 88

PF-06651600 - Drug Profile 89

PF-06700841 - Drug Profile 90

QPAL-1 - Drug Profile 92

QPAL-2 - Drug Profile 93

Recombinant Proteins to Antagonize IFN-Gamma Receptor 1 for Alopecia Areata and Graft Arteriosclerosis - Drug Profile 94

remetinostat - Drug Profile 95

ruxolitinib phosphate - Drug Profile 98

Samcyprone - Drug Profile 113

secukinumab - Drug Profile 115

setipiprant - Drug Profile 128

SM-04554 - Drug Profile 130

Small Molecule for Androgenic Alopecia - Drug Profile 132

Small Molecules to Inhibit JAK for Alopecia Areata, Androgenetic Alopecia and Dermatological Disorders - Drug Profile 133

Synthetic Peptide for Alopecia - Drug Profile 134

TASP-0382088 - Drug Profile 135

TS-133 - Drug Profile 136

VTI-1000 Series - Drug Profile 137

ZK-003 - Drug Profile 138

Alopecia - Dormant Projects 139

Alopecia - Discontinued Products 141

Alopecia - Product Development Milestones 142

Featured News & Press Releases 142

Appendix 151

Methodology 151

Coverage 151

Secondary Research 151

Primary Research 151

Expert Panel Validation 151

Contact Us 151

Disclaimer 152





List of Tables

Number of Products under Development for Alopecia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017 (Contd..1), H1 2017

Products under Development by Companies, H1 2017 (Contd..2), H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Alopecia - Pipeline by Aclaris Therapeutics Inc, H1 2017

Alopecia - Pipeline by Allergan Plc, H1 2017

Alopecia - Pipeline by Almirall SA, H1 2017

Alopecia - Pipeline by AndroScience Corp, H1 2017

Alopecia - Pipeline by Berg LLC, H1 2017

Alopecia - Pipeline by BiologicsMD Inc, H1 2017

Alopecia - Pipeline by BirchBioMed Inc, H1 2017

Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2017

Alopecia - Pipeline by Cassiopea SpA, H1 2017

Alopecia - Pipeline by Concert Pharmaceuticals Inc, H1 2017

Alopecia - Pipeline by Dong-A Socio Holdings Co Ltd, H1 2017

Alopecia - Pipeline by Follicum AB, H1 2017

Alopecia - Pipeline by Handok Inc, H1 2017

Alopecia - Pipeline by Histogen Inc, H1 2017

Alopecia - Pipeline by Hyundai Pharmaceutical Co Ltd, H1 2017

Alopecia - Pipeline by Incyte Corp, H1 2017

Alopecia - Pipeline by Kuhnil Pharmaceutical Co Ltd, H1 2017

Alopecia - Pipeline by Lee's Pharmaceutical Holdings Ltd, H1 2017

Alopecia - Pipeline by LEO Pharma A/S, H1 2017

Alopecia - Pipeline by Medivir AB, H1 2017

Alopecia - Pipeline by NovaLead Pharma Pvt Ltd, H1 2017

Alopecia - Pipeline by Novartis AG, H1 2017

Alopecia - Pipeline by Panacea Biotec Ltd, H1 2017

Alopecia - Pipeline by Pfizer Inc, H1 2017

Alopecia - Pipeline by Quark Pharmaceuticals Inc, H1 2017

Alopecia - Pipeline by RiverTown Therapeutics Inc, H1 2017

Alopecia - Pipeline by RXi Pharmaceuticals Corp, H1 2017

Alopecia - Pipeline by Samumed LLC, H1 2017

Alopecia - Pipeline by SWITCH Biotech LLC, H1 2017

Alopecia - Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H1 2017

Alopecia - Pipeline by Tigo GmbH, H1 2017

Alopecia - Pipeline by viDA Therapeutics Inc, H1 2017

Alopecia - Dormant Projects, H1 2017

Alopecia - Dormant Projects, H1 2017 (Contd..1), H1 2017

Alopecia - Discontinued Products, H1 2017





List of Figures

Number of Products under Development for Alopecia, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Top 10 Routes of Administration, H1 2017

Number of Products by Top 10 Molecule Types, H1 2017

Number of Products by Stage and Top 10 Molecule Types, H1 2017

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus